VERT-002

DRUG2 trials

Sponsors

Pierre Fabre Medicament

Conditions

MET AlterationSolid Tumorlocally advanced or metastatic solid tumors with MET alterations

Phase 1

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

RecruitingNCT06669117

Pierre Fabre MedicamentMET Alteration, Solid Tumor

Start: 2024-10-22End: 2032-10-01Target: 140Updated: 2025-07-02

A First-In-Human (FIH) phase I/II open-label, multicenter, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations

RecruitingCTIS2024-512760-64-00

Pierre Fabre Medicamentlocally advanced or metastatic solid tumors with MET alterations

Start: 2025-02-26Target: 170Updated: 2025-12-15